Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
38
EWTX Quote, Financials, Valuation and Earnings
Last price:
$14.18
Seasonality move
:
-3.88%
Day range:
$14.06 - $14.66
52-week range:
$10.60 - $38.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.50x
Volume:
692.1K
Avg. volume:
997.6K
1-year change:
-14.93%
Market cap:
$1.5B
Revenue:
--
EPS (TTM):
-$1.55
Analysts' Opinion
-
Consensus RatingEdgewise Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $39.00, Edgewise Therapeutics has an estimated upside of 172.73% from its current price of $14.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $14.30.
Fair Value
-
According to the consensus of 7 analysts, Edgewise Therapeutics has 172.73% upside to fair value with a price target of $39.00 per share.
EWTX vs. S&P 500
-
Over the past 5 trading days, Edgewise Therapeutics has underperformed the S&P 500 by -7.12% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Edgewise Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Edgewise Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Edgewise Therapeutics reported revenues of --.
Earnings Growth
-
Edgewise Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Edgewise Therapeutics reported earnings per share of -$0.43.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$82.5M | -$123.4M | -$170M | -$34.8M | -$46M | |
| EBITDA | -$81.9M | -$121.4M | -$167.7M | -$34.2M | -$45.4M | |
| Diluted EPS | -$1.32 | -$1.55 | -$1.55 | -$0.33 | -$0.43 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $310.5M | $268.6M | $333.4M | $541.4M | $443.2M | |
| Total Assets | $311.2M | $272.7M | $346.4M | $553.8M | $454.4M | |
| Current Liabilities | $4.9M | $10M | $12.7M | $14.6M | $21.1M | |
| Total Liabilities | $4.9M | $12.4M | $17.6M | $18.9M | $24.7M | |
| Total Equity | $306.4M | $260.4M | $328.8M | $534.9M | $429.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.9M | -$97.7M | -$118.3M | -$28.6M | -$37.9M | |
| Cash From Investing | -$52.9M | -$214.5M | $127.6M | -$268.3M | $43.9M | |
| Cash From Financing | $129.6M | $294.2M | $10.4M | $241.1M | $2.2M | |
| Free Cash Flow | -$72.4M | -$99.4M | -$119.4M | -$28.9M | -$37.9M | |
EWTX
Sector
Market Cap
$1.5B
$32.8M
Price % of 52-Week High
37.51%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-14.93%
-35.38%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$14.98
200-day SMA
Sell
Level
$24.09
Bollinger Bands (100)
Sell
Level
13.59 - 25.63
Chaikin Money Flow
Buy
Level
7.5M
20-day SMA
Sell
Level
$14.73
Relative Strength Index (RSI14)
Sell
Level
41.91
ADX Line
Sell
Level
10.86
Williams %R
Buy
Level
-84.7458
50-day SMA
Sell
Level
$14.55
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
20.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company’s product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Stock Forecast FAQ
In the current month, EWTX has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The EWTX average analyst price target in the past 3 months is $39.00.
-
Where Will Edgewise Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Edgewise Therapeutics share price will rise to $39.00 per share over the next 12 months.
-
What Do Analysts Say About Edgewise Therapeutics?
Analysts are divided on their view about Edgewise Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Edgewise Therapeutics is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Edgewise Therapeutics's Price Target?
The price target for Edgewise Therapeutics over the next 1-year time period is forecast to be $39.00 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is EWTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Edgewise Therapeutics is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EWTX?
You can purchase shares of Edgewise Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Edgewise Therapeutics shares.
-
What Is The Edgewise Therapeutics Share Price Today?
Edgewise Therapeutics was last trading at $14.18 per share. This represents the most recent stock quote for Edgewise Therapeutics. Yesterday, Edgewise Therapeutics closed at $14.30 per share.
-
How To Buy Edgewise Therapeutics Stock Online?
In order to purchase Edgewise Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
64
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
83
GMS alert for Jun 23
GMS [GMS] is up 0.03% over the past day.
Buy
54
SMLR alert for Jun 23
Semler Scientific [SMLR] is up 16.13% over the past day.
Buy
57
GXO alert for Jun 23
GXO Logistics [GXO] is up 2.42% over the past day.
